Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$5.57 +3.7%	$4.73	$3.42 ▼ $7.20	$313.11M	1.94	1.52 million shs	623,058 shs
CDTX Cidara Therapeutics	$24.05 +3.2%	$20.84	$10.14 ▼ $28.42	$301.76M	0.86	82,347 shs	363,087 shs
CYRX Cryoport	$6.18 +5.8%	$5.90	$4.58 ▼ $11.64	$309.85M	1.92	536,203 shs	386,732 shs
STRO Sutro Biopharma	$0.91 -0.4%	$0.81	$0.52 ▼ $5.17	$76.81M	1.77	1.09 million shs	515,843 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	+3.72%	+0.91%	+18.01%	+14.37%	-5.43%
CDTX Cidara Therapeutics	+3.22%	+5.99%	+11.86%	+1.86%	+94.89%
CYRX Cryoport	+5.82%	+4.75%	+6.74%	-7.21%	-37.39%
STRO Sutro Biopharma	-0.43%	-0.69%	-13.39%	-38.14%	-77.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACB Aurora Cannabis	0.5121 of 5 stars	0.0	2.0	0.0	2.4	0.8	0.6
CDTX Cidara Therapeutics	4.4907 of 5 stars	4.6	3.0	4.6	3.3	0.8	0.0
CYRX Cryoport	2.8914 of 5 stars	4.4	1.0	0.0	2.0	2.5	0.6
STRO Sutro Biopharma	4.1413 of 5 stars	4.1	2.0	4.7	1.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	3.67	Strong Buy	N/A	N/A
CDTX Cidara Therapeutics	3.22	Buy	$42.00	74.64% Upside
CYRX Cryoport	2.71	Moderate Buy	$11.00	77.99% Upside
STRO Sutro Biopharma	2.13	Hold	$6.11	572.34% Upside

Current Analyst Ratings Breakdown

Latest STRO, ACB, CDTX, and CYRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
6/2/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/27/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/23/2025	CDTX Cidara Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $35.00
5/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/19/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$1.00 ➝ $0.80
5/16/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $50.00
5/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$33.00 ➝ $35.00
5/9/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$46.00 ➝ $47.00
5/8/2025	CYRX Cryoport	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
5/5/2025	CYRX Cryoport	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $7.00

(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$320.81M	0.98	$0.21 per share	26.35	$8.18 per share	0.68
CDTX Cidara Therapeutics	$302K	999.19	N/A	N/A	($1.82) per share	-13.21
CYRX Cryoport	$232.13M	1.33	$0.36 per share	16.95	$9.45 per share	0.65
STRO Sutro Biopharma	$66.43M	1.16	N/A	N/A	$2.45 per share	0.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$48.62M	$0.05	111.42	12.66	N/A	0.42%	0.59%	0.42%	6/19/2025 (Estimated)
CDTX Cidara Therapeutics	-$22.93M	-$29.47	N/A	N/A	N/A	-289.05%	-69.64%	-33.73%	8/12/2025 (Estimated)
CYRX Cryoport	-$99.59M	-$2.34	N/A	N/A	N/A	-70.08%	-13.35%	-6.43%	8/5/2025 (Estimated)
STRO Sutro Biopharma	-$106.79M	-$2.98	N/A	N/A	N/A	-77.01%	-101.89%	-28.69%	8/12/2025 (Estimated)

Latest STRO, ACB, CDTX, and CYRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/19/2025	Q4 2025	ACB Aurora Cannabis	$0.11	N/A	N/A	N/A	$88.85 million	N/A
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/8/2025	Q1 2025	STRO Sutro Biopharma	-$0.63	-$0.91	-$0.28	-$0.91	$11.61 million	$17.40 million
5/7/2025	Q1 2025	CYRX Cryoport	-$0.23	-$0.22	+$0.01	-$0.28	$56.19 million	$41.04 million
3/13/2025	Q4 2024	STRO Sutro Biopharma	-$0.86	-$2.96	-$2.10	-$0.89	$10.44 million	$14.00 million
3/6/2025	Q4 2024	CDTX Cidara Therapeutics	-$5.28	-$5.38	-$0.10	-$5.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
CYRX Cryoport	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.07	3.30	1.60
CDTX Cidara Therapeutics	N/A	3.54	3.54
CYRX Cryoport	0.48	5.70	5.32
STRO Sutro Biopharma	N/A	3.09	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
CDTX Cidara Therapeutics	35.82%
CYRX Cryoport	92.90%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
CDTX Cidara Therapeutics	3.89%
CYRX Cryoport	10.00%
STRO Sutro Biopharma	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,340	56.21 million	54.85 million	Optionable
CDTX Cidara Therapeutics	90	12.55 million	6.51 million	No Data
CYRX Cryoport	1,020	50.14 million	44.44 million	Optionable
STRO Sutro Biopharma	240	84.46 million	77.59 million	Optionable

STRO, ACB, CDTX, and CYRX Headlines

Recent News About These Companies

Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Update

June 3 at 12:59 PM | marketbeat.com

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

June 2 at 6:54 PM | finance.yahoo.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by Brokerages

May 24, 2025 | marketbeat.com

Point72 Asset Management L.P. Has $4.04 Million Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)

May 22, 2025 | marketbeat.com

2,570,000 Shares in Sutro Biopharma, Inc. (NASDAQ:STRO) Purchased by Vestal Point Capital LP

May 21, 2025 | marketbeat.com

Suvretta Capital Management LLC Grows Position in Sutro Biopharma, Inc. (NASDAQ:STRO)

May 19, 2025 | marketbeat.com

MPM Bioimpact LLC Has $3.98 Million Position in Sutro Biopharma, Inc. (NASDAQ:STRO)

May 16, 2025 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Releases Earnings Results, Misses Expectations By $0.28 EPS

May 14, 2025 | marketbeat.com

Sutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 9, 2025 | finanznachrichten.de

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025 | globenewswire.com

Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday

May 7, 2025 | marketbeat.com

Sutro Biopharma to Participate in Upcoming Investor Conferences

May 1, 2025 | globenewswire.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 21.92%

April 26, 2025 | aaii.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%

April 1, 2025 | aaii.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%

March 18, 2025 | aaii.com

Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright

March 17, 2025 | markets.businessinsider.com

HC Wainwright & Co. Downgrades Sutro Biopharma (STRO)

March 17, 2025 | msn.com

Sutro Biopharma presents expanded data from REFRalphaME-01 trial

March 17, 2025 | markets.businessinsider.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

D-Wave Pushes Back on Short Seller Case With Strong Earnings
By Nathan Reiff | May 14, 2025
View D-Wave Pushes Back on Short Seller Case With Strong Earnings
Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
By Chris Markoch | May 12, 2025
View Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
If the U.S.-China Trade Reset Holds, These 3 Stocks Could Fly
By Chris Markoch | May 16, 2025
View If the U.S.-China Trade Reset Holds, These 3 Stocks Could Fly
Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum
By Jeffrey Neal Johnson | May 22, 2025
View Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum
3 Top-Rated Energy Companies Staging Strong Recoveries
By Nathan Reiff | June 2, 2025
View 3 Top-Rated Energy Companies Staging Strong Recoveries

STRO, ACB, CDTX, and CYRX Company Descriptions

Aurora Cannabis NASDAQ:ACB

$5.57 +0.20 (+3.72%)

As of 06/4/2025 04:00 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Cidara Therapeutics NASDAQ:CDTX

$24.05 +0.75 (+3.22%)

As of 06/4/2025 04:00 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cryoport NASDAQ:CYRX

$6.18 +0.34 (+5.82%)

As of 06/4/2025 04:00 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Sutro Biopharma NASDAQ:STRO

$0.91 0.00 (-0.43%)

As of 06/4/2025 04:00 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time